In this insightful discussion, Sarel Fleishman, a biomolecular sciences professor, dives into structure prediction and the need for robust benchmarking in AI/ML. Max Vasquez, Chief Computing Officer at Adimab, shares how large synthetic antibody libraries can streamline discovery. Arvind Rajpal emphasizes the importance of de novo design for tricky epitopes, while Vincent Ling highlights AI’s broader impacts on productivity within pharmaceutical companies. Together, they explore the challenges and potential of combining traditional methods with cutting-edge technology in biotherapeutic research.
